Neuphoria Therapeutics Inc. (NEUP)

Every figure this model derived for NEUP, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 19,440,655 CashAndCashEquivalentsAtCarryingValue 2026-03-31
current assets 21,657,908 AssetsCurrent 2026-03-31
current liabilities 1,513,309 LiabilitiesCurrent 2026-03-31
equity 29,423,944 StockholdersEquity 2026-03-31
interest expense 17,433 InterestPaidNet 2025-06-30
ocf -17,152,001 NetCashProvidedByUsedInOperatingActivities 2026-03-31
revenue 15,649,448 RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30
sbc 373,531 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up NEUP on one particular measure came for.

RatioValue
cash operating margin-100.47
current ratio14.31
current ratio reported14.31
dilution pct95.1
fcf margin-109.6
interest cover-961.41
operating margin-107.1
owner earnings margin-111.99
roic-132.63
sbc pct revenue2.39

What to be careful about

What this model itself distrusts about NEUP's figures. Written by the derivation as it ran, not added afterwards.